Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$138.37 -1.4%	$141.88	$128.51 ▼ $238.00	$20.25B	0.01	1.30 million shs	1.09 million shs
BMRN BioMarin Pharmaceutical	$71.44 -1.9%	$67.46	$60.63 ▼ $94.85	$13.63B	0.33	1.84 million shs	1.25 million shs
IONS Ionis Pharmaceuticals	$31.15 -1.8%	$32.53	$30.23 ▼ $52.34	$4.95B	0.28	1.45 million shs	799,700 shs
UTHR United Therapeutics	$306.97 -0.3%	$340.06	$221.53 ▼ $417.82	$13.79B	0.64	450,767 shs	223,177 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-1.40%	-1.80%	-1.52%	-8.55%	-36.04%
BMRN BioMarin Pharmaceutical	-1.91%	+0.28%	+3.82%	+6.80%	-19.38%
IONS Ionis Pharmaceuticals	-1.80%	-5.35%	-1.92%	-13.26%	-30.25%
UTHR United Therapeutics	-0.34%	-1.92%	-3.74%	-14.72%	+26.18%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.9023 of 5 stars	4.2	5.0	3.7	3.4	2.5	1.9
BMRN BioMarin Pharmaceutical	4.9247 of 5 stars	4.4	3.0	3.3	3.3	2.5	3.1
IONS Ionis Pharmaceuticals	4.3237 of 5 stars	4.4	2.0	3.0	2.6	2.5	0.6
UTHR United Therapeutics	4.9332 of 5 stars	3.3	4.0	4.6	3.5	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.43	Hold	$213.33	54.18% Upside
BMRN BioMarin Pharmaceutical	2.71	Moderate Buy	$94.00	31.58% Upside
IONS Ionis Pharmaceuticals	2.70	Moderate Buy	$59.44	90.83% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$388.25	26.48% Upside

Current Analyst Ratings Breakdown

Latest IONS, BIIB, UTHR, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$47.00 ➝ $45.00
3/11/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$51.00 ➝ $47.00
2/27/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00
2/24/2025	BMRN BioMarin Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$98.00
2/20/2025	BMRN BioMarin Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$94.00
2/20/2025	BMRN BioMarin Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$81.00 ➝ $82.00
2/20/2025	BMRN BioMarin Pharmaceutical	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$78.00 ➝ $80.00
2/20/2025	BMRN BioMarin Pharmaceutical	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$70.00 ➝ $70.00
2/20/2025	BMRN BioMarin Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00
2/20/2025	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$109.00 ➝ $113.00
2/20/2025	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$122.00 ➝ $126.00

(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.09	$22.72 per share	6.09	$114.71 per share	1.21
BMRN BioMarin Pharmaceutical	$2.85B	4.78	$3.37 per share	21.17	$29.69 per share	2.41
IONS Ionis Pharmaceuticals	$705.14M	7.02	N/A	N/A	$3.70 per share	8.42
UTHR United Therapeutics	$2.88B	4.79	$18.46 per share	16.63	$127.35 per share	2.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$11.19	12.37	8.38	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$167.65M	$2.20	32.47	16.39	0.61	14.96%	9.91%	7.65%	4/23/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$366.29M	-$3.04	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	5/6/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$24.60	13.48	11.17	0.97	40.31%	19.22%	16.15%	4/29/2025 (Estimated)

Latest IONS, BIIB, UTHR, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/23/2025	N/A	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
4/23/2025	N/A	BMRN BioMarin Pharmaceutical	$0.95	N/A	N/A	N/A	$741.84 million	N/A
2/26/2025	Q4 24	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/19/2025	Q4 2024	BMRN BioMarin Pharmaceutical	$0.54	$0.72	+$0.18	$0.64	$711.05 million	$747.31 million
2/19/2025	Q4 24	IONS Ionis Pharmaceuticals	-$1.12	-$0.66	+$0.46	-$0.66	$140.97 million	$227.00 million
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
BMRN BioMarin Pharmaceutical	0.11	5.33	2.62
IONS Ionis Pharmaceuticals	2.12	8.47	8.82
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
IONS Ionis Pharmaceuticals	93.86%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
BMRN BioMarin Pharmaceutical	1.85%
IONS Ionis Pharmaceuticals	2.71%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
BMRN BioMarin Pharmaceutical	3,401	190.78 million	187.06 million	Optionable
IONS Ionis Pharmaceuticals	800	158.97 million	153.62 million	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

IONS, BIIB, UTHR, and BMRN Headlines

Recent News About These Companies

Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March?

March 28 at 7:40 PM | insidermonkey.com

3 Reasons Investors Watch United Therapeutics (UTHR)

March 28 at 4:26 PM | msn.com

United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound?

March 28 at 4:26 PM | msn.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Eagle Health Investments LP

March 28 at 6:58 AM | marketbeat.com

Prudential Financial Inc. Purchases 12,104 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 28 at 4:50 AM | marketbeat.com

Tommy G. Thompson Sells 2,500 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

March 26 at 7:45 PM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson Sells 2,500 Shares

March 26 at 5:15 AM | insidertrades.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Corebridge Financial Inc.

March 26 at 5:14 AM | marketbeat.com

First Week of November 21st Options Trading For United Therapeutics (UTHR)

March 26 at 4:48 AM | nasdaq.com

Fox Run Management L.L.C. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

March 26 at 4:32 AM | marketbeat.com

KLP Kapitalforvaltning AS Invests $15.28 Million in United Therapeutics Co. (NASDAQ:UTHR)

March 25, 2025 | marketbeat.com

Teacher Retirement System of Texas Acquires 1,626 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 25, 2025 | marketbeat.com

1,287 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by AXQ Capital LP

March 24, 2025 | marketbeat.com

Summit Global Investments Has $12.73 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

March 23, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Stock Position Trimmed by Natixis Advisors LLC

March 23, 2025 | marketbeat.com

Investing Action Plan: Anduril Industries, United Therapeutics, Barstool In Miami

March 23, 2025 | investors.com

Harvest Fund Management Co. Ltd Purchases 2,021 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 22, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Corient Private Wealth LLC

March 22, 2025 | marketbeat.com

Buy Recommendation for United Therapeutics: Undervalued Potential in IPF Treatment with Tyvaso

March 21, 2025 | tipranks.com

Generali Asset Management SPA SGR Invests $3.01 Million in United Therapeutics Co. (NASDAQ:UTHR)

March 21, 2025 | marketbeat.com

Zacks Research Issues Pessimistic Outlook for UTHR Earnings

March 21, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA Insiders Sell: This Is What It Means for the Market
By Thomas Hughes | March 25, 2025
View NVIDIA Insiders Sell: This Is What It Means for the Market
3 Energy Stocks With Cheap Valuations and Big Returns Ahead
By Sarah Horvath | March 19, 2025
View 3 Energy Stocks With Cheap Valuations and Big Returns Ahead
5 ETFs Poised to Spring Ahead in the Second Quarter
By Chris Markoch | March 11, 2025
View 5 ETFs Poised to Spring Ahead in the Second Quarter
3 Stocks to Buy While Others Stay on the Sidelines
By Chris Markoch | March 8, 2025
View 3 Stocks to Buy While Others Stay on the Sidelines
Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
By Gabriel Osorio-Mazilli | March 24, 2025
View Super Micro Stock: $7.2M Call Options Signal Big Upside Potential

IONS, BIIB, UTHR, and BMRN Company Descriptions

Biogen NASDAQ:BIIB

$138.37 -1.96 (-1.40%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$137.85 -0.52 (-0.37%)

As of 03/28/2025 07:49 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$71.44 -1.39 (-1.91%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$70.05 -1.39 (-1.95%)

As of 03/28/2025 06:27 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Ionis Pharmaceuticals NASDAQ:IONS

$31.15 -0.57 (-1.80%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$31.27 +0.12 (+0.39%)

As of 03/28/2025 06:34 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

United Therapeutics NASDAQ:UTHR

$306.97 -1.05 (-0.34%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$309.06 +2.09 (+0.68%)

As of 03/28/2025 07:16 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time